Effects of Sulforaphane on SARS‑CoV‑2 infection and NF‑κB dependent expression of genes involved in the COVID‑19 'cytokine storm'.
Level 5 - mechanism / opinion, no new human data
In vitro cell line and in silico molecular modeling study without in vivo or human data.
PubMed 37477130 · doi:10.3892/ijmm.2023.5279
What was done
Researchers evaluated the effect of sulforaphane (SFN) on SARS-CoV-2 replication and inflammatory cytokine expression in human bronchial epithelial Calu-3 cells. Viral replication (N-protein RNA) and pro-inflammatory gene expression (IL-1β, IL-8) were measured using reverse transcription quantitative droplet digital PCR (RT-ddPCR), and NF-κB protein levels were assessed via western blotting. In addition, molecular dynamics simulations (Gromacs 2021.1) were performed to analyze physical interactions between SFN, NF-κB, and DNA.
What was found
The abstract reports directional findings without specific numerical values. Computational simulations showed SFN stably bound NF-κB, forming a ternary complex that impaired proper DNA binding and stabilized an inactive state. In Calu-3 cells, SFN inhibited SARS-CoV-2 replication (lowering N-protein RNA levels), decreased NF-κB protein expression, and reduced downstream IL-1β and IL-8 gene expression.
Why it matters
This study provides mechanistic cell-level evidence that sulforaphane can simultaneously modulate viral replication and key NF-κB-driven inflammatory pathways implicated in COVID-19.
Limits
The study is limited to in vitro cell culture and computational modeling, with no validation in animal models or clinical human trials. The abstract omits all numerical data, including tested concentrations, IC50 values, effect sizes, and statistical confidence intervals. Pharmacokinetics and therapeutic safety margins in humans remain unassessed.
Cited by
- supports There are published scientific papers demonstrating direct antiviral effects of sulforaphane.